Digoxin reduces 30-day all-cause hospital admission in older patients with chronic systolic heart failure

American Journal of Medicine

Volumn 126, Issue 8, 2013, Pages 701-708

  Bourge, Robert C ^a   Fleg, Jerome L ^b   Fonarow, Gregg C ^c   Cleland, John G F ^d   McMurray, John J V ^e   Van Veldhuisen, Dirk J ^f   Gheorghiade, Mihai ^g   Patel, Kanan ^a   Aban, Inmaculada B ^a   Allman, Richard M ^a,h   White Williams, Connie ^a   White, Michel ⁱ   Filippatos, Gerasimos S ^j   Anker, Stefan D ^k   Ahmed, Ali ^a,h  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF HULL   (United Kingdom)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^g NORTHWESTERN UNIVERSITY   (United States)

^h BIRMINGHAM VA MEDICAL CENTER   (United States)

ⁱ MONTREAL HEART INSTITUTE   (Canada)

^j NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^k IRCCS SAN RAFFAELE PISANA   (Italy)

more..

Author keywords

30 day all cause hospital admission; Digoxin; Heart failure

Indexed keywords

DIGOXIN; PLACEBO;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; HEART EJECTION FRACTION; HIGH RISK PATIENT; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC HEART FAILURE; TREATMENT DURATION;

30-DAY ALL-CAUSE HOSPITAL ADMISSION; DIGOXIN; HEART FAILURE;

AGED; CARDIOTONIC AGENTS; DIGOXIN; FEMALE; HEART FAILURE, SYSTOLIC; HOSPITALIZATION; HUMANS; MALE; PATIENT PROTECTION AND AFFORDABLE CARE ACT; TREATMENT OUTCOME; UNITED STATES;

EID: 84880610770     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2013.02.001     Document Type: Article

References (30)

1. H.J. Jiang, C.A. Russo, and M.L. Barrett Nationwide Frequency and Costs of Potentially Preventable Hospitalizations, 2006 HCUP Statistical Brief #72 April 2009 US Agency for Healthcare Research and Quality Rockville, MD http://www.hcup-us.ahrq.gov/reports/statbriefs/sb72.pdf Accessed February 14, 2013
2. S.F. Jencks, M.V. Williams, and E.A. Coleman Rehospitalizations among patients in the Medicare fee-for-service program N Engl J Med 360 2009 1418 1428
3. J. Stone, and G.J. Hoffman Medicare Hospital Readmissions: Issues, Policy Options and PPACA: Congressional Research Service Report for Congress Prepared for Members and Committees of Congress 2010 Congressional Research Service Washington, DC
4. The Centers for Medicare & Medicaid Services Readmissions reduction program http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ AcuteInpatientPPS/Readmissions-Reduction-Program.html Accessed December 28, 2012
5. J. Rau Hospitals face pressure to avert readmissions The New York Times November 27, 2012 D1 http://www.nytimes.com/2012/11/27/health/hospitals-face- pressure-from-medicare-to-avert-readmissions.html?-r=0 Accessed December 2, 2012
6. The Digitalis Investigation Group Investigators The effect of digoxin on mortality and morbidity in patients with heart failure N Engl J Med 336 1997 525 533
7. W.B. Hood Jr, A.L. Dans, G.H. Guyatt, R. Jaeschke, and J.J. McMurray Digitalis for treatment of congestive heart failure in patients in sinus rhythm Cochrane Database Syst Rev 2004 CD002901
8. M. Gheorghiade, D.J. van Veldhuisen, and W.S. Colucci Contemporary use of digoxin in the management of cardiovascular disorders Circulation 113 2006 2556 2564
9. M. Gheorghiade, and E. Braunwald Reconsidering the role for digoxin in the management of acute heart failure syndromes JAMA 302 2009 2146 2147
10. The Digitalis Investigation Group Rationale, design, implementation, and baseline characteristics of patients in the DIG trial: a large, simple, long-term trial to evaluate the effect of digitalis on mortality in heart failure Control Clin Trials 17 1996 77 97
11. J.F. Collins, C.L. Howell, A. Horney, and D.I.G. Invest Determination of vital status at the end of the DIG trial Control Clin Trials 24 2003 726 730
12. A. Ahmed, F. Waagstein, and B. Pitt Effectiveness of digoxin in reducing one-year mortality in chronic heart failure in the Digitalis Investigation Group trial Am J Cardiol 103 2009 82 87
13. M. Gheorghiade, K. Patel, and G.S. Flippatos Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial Eur J Heart Fail 2013 Jan 25 [Epub ahead of print]
14. M. Packer, M. Gheorghiade, and J.B. Young Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors RADIANCE Study N Engl J Med 329 1993 1 7
15. B.F. Uretsky, J.B. Young, F.E. Shahidi, L.G. Yellen, M.C. Harrison, and M.K. Jolly Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial PROVED Investigative Group J Am Coll Cardiol 22 1993 955 962
16. P.M. Rothwell Treating individuals 2 Subgroup analysis in randomised controlled trials: importance, indications, and interpretation Lancet 365 2005 176 186
17. R. Garg, and S. Yusuf Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure Collaborative Group on ACE Inhibitor Trials JAMA 273 1995 1450 1456
18. H. Krum, E.B. Roecker, and P. Mohacsi Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study JAMA 289 2003 712 718
19. B. Pitt, H. White, and J. Nicolau Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure J Am Coll Cardiol 46 2005 425 431
20. G.C. Fonarow, W.T. Abraham, and N.M. Albert Association between performance measures and clinical outcomes for patients hospitalized with heart failure JAMA 297 2007 61 70
21. C.M. O'Connor, R.C. Starling, and A.F. Hernandez Effect of nesiritide in patients with acute decompensated heart failure N Engl J Med 365 2011 32 43
22. M. Packer, J.R. Carver, and R.J. Rodeheffer Effect of oral milrinone on mortality in severe chronic heart failure The PROMISE Study Research Group N Engl J Med 325 1991 1468 1475
23. J.R. Teerlink, G. Cotter, and B.A. Davison Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial Lancet 381 2013 29 39
24. G.K. Mulvey, Y. Wang, and Z. Lin Mortality and readmission for patients with heart failure among U.S. News & World Report's top heart hospitals Circ Cardiovasc Qual Outcomes 2 2009 558 565
25. G.C. Fonarow, W.G. Stough, and W.T. Abraham Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry J Am Coll Cardiol 50 2007 768 777
26. A. Ahmed, M.W. Rich, and J.L. Fleg Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial Circulation 114 2006 397 403
27. B. Pitt, F. Zannad, and W.J. Remme The effect of spironolactone on morbidity and mortality in patients with severe heart failure Randomized Aldactone Evaluation Study Investigators N Engl J Med 341 1999 709 717
28. The SOLVD Investigators Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure N Engl J Med 325 1991 293 302
29. C.B. Granger, J.J. McMurray, and S. Yusuf Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial Lancet 362 2003 772 776
30. F. Zannad, J.J. McMurray, and H. Krum Eplerenone in patients with systolic heart failure and mild symptoms N Engl J Med 364 2011 11 21